MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Matrixyl Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS) is a topical cosmetic matrikine peptide that joins the procollagen-I fragment KTTKS to a palmitic-acid tail. KTTKS is a natural feedback signal released during collagen processing; applied to fibroblasts it raises type I/III collagen and fibronectin synthesis (PMID 8486721), and the palmitoyl chain lets the peptide partition into skin (PMID 25143811). Developed by Sederma and launched in 2000, it is used in leave-on serums and creams at roughly 3 ppm (0.0003%) and applied twice daily; a 12-week double-blind split-face trial reported significant wrinkle and fine-line improvement versus placebo with excellent tolerability (PMID 18492182). Matrixyl is not absorbed systemically and is regulated as a cosmetic ingredient, not an approved drug. The subcutaneous reconstitution figures on this page are an educational measurement convention only — the real route is topical.
Reconstitute: Add 3 mL bacteriostatic water → 3.33 mg/mL concentration.
Typical dose: Topical 3 ppm (0.0003%) pal-KTTKS, applied twice daily
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL = 0.0333 mg (33 mcg) on a U-100 insulin syringe.
Storage: Lyophilized powder stored frozen at −20 °C; reconstituted solution refrigerated at 2-8 °C and used within ~4 weeks; finished topical products stored at room temperature, protected from light and air.
Half-life: No meaningful plasma half-life — Matrixyl is topical and not systemically absorbed. Palmitoylation makes Pal-KTTKS more protease-resistant than free KTTKS, but dermal peptidases still degrade it within hours, hence twice-daily reapplication [4].
Route: Topical (leave-on serums and creams at ~3 ppm Pal-KTTKS, applied twice daily). The subcutaneous reconstitution figures shown here are an educational measurement reference only, not a real delivery route.
Status: Cosmetic ingredient, not an FDA- or EMA-approved drug; reviewed as safe-as-used in topical cosmetics by the Cosmetic Ingredient Review (2024) [7].
About Matrixyl
Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS) is a topical cosmetic matrikine peptide built from the collagen-fragment sequence KTTKS conjugated to palmitic acid [1][2]. Clinically and commercially it is used topically, not by injection: leave-on serums and moisturizers are formulated at about 3 ppm (0.0003%) Pal-KTTKS and applied to the face twice daily, the regimen validated in a 12-week placebo-controlled split-face trial [3]. The subcutaneous reconstitution math below is an educational measurement reference that mirrors how this site presents every compound; it is not how Matrixyl is actually delivered.\n\nThis guide models a 10 mg vial reconstituted with 3.0 mL of bacteriostatic water (3.33 mg/mL) so the educational doses land in an easily read range on a U-100 insulin syringe: 333 mcg ≈ 10 units, 500 mcg ≈ 15 units, and 667 mcg ≈ 20 units. A complete Matrixyl dosage discussion therefore has two layers — the real topical figure (3 ppm, twice daily) and these educational per-application equivalents. Because the peptide is not systemically absorbed, there is no titration for tolerance the way there is with injectable peptides; the schedule below simply ramps the educational dose for illustration [4].\n\nFrequency: Twice daily, morning and evening, mirroring the twice-daily topical application studied for Pal-KTTKS. Matrixyl is a cosmetic ingredient, not an FDA- or EMA-approved drug, and the figures here are educational only.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 10 mg Matrixyl vial; do not aim the stream directly at the powder, and do not shake.
Gently swirl or roll the vial until the solution is completely clear; the result is a 3.33 mg/mL concentration (about 33 mcg per insulin-syringe unit).
Store refrigerated at 2-8 °C and draw the educational dose for the current phase (333 mcg ≈ 10 units, 500 mcg ≈ 15 units, 667 mcg ≈ 20 units).
Educational note: Matrixyl is used TOPICALLY twice daily at ~3 ppm, not by injection — these subcutaneous figures are a measurement convention only; for any modeled subcutaneous injection, deliver slowly and wait a few seconds before withdrawing the needle.
Interactive Matrixyl Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 3mL water yields 3.33 mg/mL. To evaluate a 250mcg dose, pull to 7.5 units (8 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Weeks 1-4 (introductory) | 333 mcg | 10 units (0.10 mL) |
| Weeks 5-8 (standard) | 500 mcg | 15 units (0.15 mL) |
| Weeks 9-12+ (maintenance) | 667 mcg | 20 units (0.20 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (Matrixyl, 10 mg each):
- check8 weeks ≈ 5 vials (introductory + standard phases)
- check12 weeks ≈ 9 vials
- check16 weeks ≈ 13 vials
Insulin Syringes (U-100):
- checkPer week: 14 syringes (2/day)
- check8 weeks: 112 syringes
- check12 weeks: 168 syringes
- check16 weeks: 224 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- check12 weeks (9 vials): 27 mL → 3 × 10 mL bottles
- check16 weeks (13 vials): 39 mL → 4 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each injection.
- checkPer week: 28 swabs (4/day across two injections)
- check8 weeks: 224 swabs → 3 × 100-count boxes
- check12 weeks: 336 swabs → 4 × 100-count boxes
- check16 weeks: 448 swabs → 5 × 100-count boxes
Mechanism of Action (MOA)
Matrixyl is the trade name for palmitoyl pentapeptide-4 (INCI), historically called palmitoyl pentapeptide-3 before the 2006 nomenclature revision. Its structure is Pal-Lys-Thr-Thr-Lys-Ser (Pal-KTTKS): the pentapeptide KTTKS linked at its N-terminus to a 16-carbon palmitoyl (palmitic-acid) chain. The molecule has the formula C39H75N7O10, a molar mass of roughly 802 g/mol, and CAS number 214047-00-4. KTTKS is not an arbitrary sequence — it is a matrikine, a fragment corresponding to residues 212-216 of the C-terminal propeptide of the proα1 chain of type I procollagen that is released when procollagen is processed into mature collagen [1].\n\nKatayama and colleagues first showed in 1993 that this procollagen subfragment, applied to subconfluent fibroblasts, drives a dose- and time-dependent increase in type I collagen, type III collagen, and fibronectin synthesis, behaving as a positive feedback signal that tells fibroblasts to keep building extracellular matrix [1]. Pal-KTTKS exploits that signal cosmetically: by interacting with fibroblasts and activating matrix-renewal gene programs, it is proposed to stimulate neosynthesis of collagen, glycosaminoglycans, and other dermal matrix macromolecules, partially restoring the structural support that declines in photoaged skin [2][5]. Jones and colleagues demonstrated that the palmitoylated peptide (C16-KTTKS) stimulates collagen production in human fibroblasts in a concentration-dependent manner that tracks its self-assembly into nanostructures near the critical aggregation concentration [5]. Beyond synthesis, Pal-KTTKS reduces α-smooth-muscle-actin expression and the trans-differentiation of fibroblasts into contractile myofibroblasts, suggesting a modulating rather than purely stimulatory role in matrix remodeling [6].\n\nFree KTTKS is too hydrophilic and unstable to penetrate skin, so the palmitoyl tail is the functional core of the design: it confers lipophilicity for partitioning into the lipid-rich stratum corneum and improves resistance to peptidases [2][4]. In an in vitro human-skin permeation study, Choi and colleagues found Pal-KTTKS was more stable than unmodified KTTKS and was detectable in the stratum corneum (~4.2 μg/cm²), epidermis (~2.8 μg/cm²), and dermis (~0.3 μg/cm²), whereas free KTTKS was undetectable in every layer; importantly, neither peptide crossed full-thickness skin into the receptor compartment [4]. Liposomal and other encapsulation strategies are actively studied to push more peptide into the viable epidermis and dermis [8].\n\nPharmacokinetics in the conventional sense barely apply. Matrixyl is delivered topically, is not meaningfully absorbed into the systemic circulation, and therefore has no clinically relevant plasma half-life. Its working duration is governed by local persistence in the skin, where palmitoylation slows enzymatic breakdown but dermal peptidases still degrade it over hours — the pharmacologic rationale for twice-daily reapplication [3][4]. The real-world route is topical at roughly 3 ppm in leave-on formulas; the subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site, not a validated delivery method. Matrixyl is regulated as a cosmetic ingredient rather than a drug and was reviewed as safe as used by the Cosmetic Ingredient Review [7].
Clinical Trial Efficacy Highlights
- starKatayama and colleagues (1993, Journal of Biological Chemistry) established the mechanistic foundation, showing that the C-terminal procollagen-I subfragment containing the KTTKS sequence augmented extracellular matrix production in cultured fibroblasts, stimulating type I collagen, type III collagen, and fibronectin synthesis in a dose- and time-dependent manner [1].
- starRobinson and colleagues (2005, International Journal of Cosmetic Science) ran the pivotal 12-week, double-blind, placebo-controlled, split-face randomized clinical study of a moisturizer containing 3 ppm pal-KTTKS; the active side produced significant improvement versus the placebo control in wrinkles and fine lines by both quantitative image analysis and expert grading, with significant subject-reported improvement and good tolerability [3].
- starChoi and colleagues (2014, Biomolecules & Therapeutics) compared KTTKS and palmitoyl-KTTKS in dermal stability and in vitro human-skin permeation, finding pal-KTTKS more stable and detectable in the stratum corneum (~4.2 μg/cm²), epidermis (~2.8 μg/cm²), and dermis (~0.3 μg/cm²), while unmodified KTTKS was undetectable in all layers and neither peptide crossed full-thickness skin into the receptor fluid [4].
- starJones and colleagues (2013, Molecular Pharmaceutics) showed that the peptide amphiphile C16-KTTKS (pal-KTTKS) stimulates collagen production in human fibroblasts in a concentration-dependent fashion that closely tracks its self-assembly near the critical aggregation concentration, linking the molecule's nanostructure formation to its collagen-stimulating activity [5].
- starPark and colleagues (2017, Tissue Engineering and Regenerative Medicine) reported that Pal-KTTKS at 0.1 μM roughly halved the proportion of α-smooth-muscle-actin-positive stress-fiber-bearing fibroblasts (about 75% down to 39%) and dose-dependently reduced fibroblast-to-myofibroblast trans-differentiation, indicating a regulatory effect on the contractile/fibrotic phenotype relevant to scarring [6].
- starLintner and Peschard (2000, International Journal of Cosmetic Science) — the foundational Sederma publication — documented how conjugating bioactive peptide sequences such as KTTKS to long-chain fatty acids improves skin penetration and converts a laboratory matrikine into a functional collagen-stimulating skincare active [2].
- starThe Cosmetic Ingredient Review Expert Panel (2024) concluded that Palmitoyl Pentapeptide-4 (alongside Myristoyl Pentapeptide-4 and Pentapeptide-4) is safe in the present practices of use and concentration, citing limited in vitro percutaneous absorption, negative genotoxicity findings, and negative results for a formulation containing 0.12% Palmitoyl Pentapeptide-4 [7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningTopical use is generally very well tolerated; the most common adverse effects are limited to mild, transient erythema, stinging, or a sensation of tightness at the application site, often when layered with other actives such as retinoids, vitamin C, or exfoliating acids [3][7].
- warningAllergic contact dermatitis to pal-KTTKS itself is uncommon, but reactions to other components of a finished cosmetic (preservatives, fragrances, emulsifiers, or penetration enhancers) can cause eczematous patches and should be evaluated by a dermatologist if persistent.
- warningBecause finished products are applied to the face, accidental ocular contact may cause transient eye irritation, watering, and burning; keep product away from the eye margin and rinse with water if it migrates onto the ocular surface.
- warningSystemic side effects have not been reported and are not expected: in vitro permeation shows pal-KTTKS reaches the stratum corneum, epidermis, and upper dermis but does not cross full-thickness skin into the circulation, so there is negligible systemic exposure [4].
- warningPregnancy, lactation, and pediatric safety data are limited; the Cosmetic Ingredient Review noted gaps in developmental/reproductive toxicity and carcinogenicity data, offset by the low maximum use concentrations (around 0.12% or less), limited percutaneous absorption, and negative genotoxicity results [7].
- warningReported anti-aging efficacy is real but modest and gradual, and several supportive datasets are manufacturer-sponsored; effects build over weeks of consistent twice-daily use and reverse on discontinuation, so claims of dramatic or rapid wrinkle removal are not supported [2][3].
- warningThe subcutaneous reconstitution and injection figures on this page are an educational measurement convention only — Matrixyl is not formulated, validated, or approved for injection, and injecting cosmetic-grade material carries real risks of contamination, sterility failure, and adverse local reactions.
- warningRegulatory/research status: Matrixyl is regulated as a cosmetic ingredient in the United States and European Union, not as an FDA- or EMA-approved drug; it has no approved oral or injectable indication and was reviewed as safe-as-used (topical) by the Cosmetic Ingredient Review in 2024 [7].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Matrixyl dosage?expand_more
The established Matrixyl dosage is topical, not injectable: finished serums and creams are formulated at roughly 3 ppm (0.0003%) palmitoyl pentapeptide-4 (Pal-KTTKS) and applied to clean facial skin twice daily, morning and evening. That 3 ppm level is the concentration validated in the 12-week split-face clinical study. The subcutaneous per-injection figures on this page (333-667 mcg, ramped across phases) are an educational reconstitution reference to match how this site presents every compound; they are not how Matrixyl is actually dosed.
Is Matrixyl FDA approved?expand_more
No. Matrixyl is not an FDA-approved drug. It is regulated as a cosmetic ingredient in the United States and European Union and is sold under trade names by Sederma/Croda and others. As a cosmetic active it does not undergo drug-style FDA approval, but it must comply with cosmetic safety rules; the independent Cosmetic Ingredient Review concluded in 2024 that Palmitoyl Pentapeptide-4 is safe as used in cosmetics. It has no approved oral or injectable indication in any jurisdiction.
How do you reconstitute Matrixyl for the educational protocol?expand_more
For Matrixyl reconstitution in this educational model, draw 3.0 mL of bacteriostatic water and inject it slowly down the wall of a 10 mg vial, then swirl gently until clear. That yields a 3.33 mg/mL solution (about 33 mcg per U-100 insulin-syringe unit), so 333 mcg is 10 units, 500 mcg is 15 units, and 667 mcg is 20 units. Remember this is a measurement convention only — in real use Matrixyl is applied topically at ~3 ppm, never reconstituted or injected.
What is the half-life of Matrixyl?expand_more
Matrixyl has no meaningful plasma half-life because it is applied topically and is not absorbed into the systemic circulation; in vitro studies show Pal-KTTKS reaches the stratum corneum, epidermis, and upper dermis but does not cross full-thickness skin. Its functional duration is set by local persistence in the skin, where the palmitoyl chain slows enzymatic breakdown but dermal peptidases still degrade it within hours. That short skin residence is the rationale for twice-daily reapplication rather than a systemic dosing interval.
Can Matrixyl be stacked with other peptides in a skincare protocol?expand_more
Yes. In topical cosmetic formulations Matrixyl is frequently combined with other actives such as Matrixyl 3000 partners, GHK-Cu copper peptide, SNAP-8, Argireline, hyaluronic acid, niacinamide, and antioxidants, and it is generally compatible with retinoids and vitamin C. A practical Matrixyl protocol applies it twice daily and introduces one new active at a time; layering several potent actives at once can increase the chance of irritation, the main category of Matrixyl side effects.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Matrixyl, plus the universal dosing calculator.
Academic References & Study Citations
Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268(14):9941-9944. View Scientific Paper →
Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci. 2000;22(3):207-218. View Scientific Paper →
Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. View Scientific Paper →
Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-327. View Scientific Paper →
Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol Pharm. 2013;10(3):1063-1069. View Scientific Paper →
Park H, An E, Cho Lee AR. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression. Tissue Eng Regen Med. 2017;14(1):73-80. View Scientific Paper →
Cosmetic Ingredient Review Expert Panel. Safety Assessment of Myristoyl Pentapeptide-4, Palmitoyl Pentapeptide-4, and Pentapeptide-4 as Used in Cosmetics. Final Report, 2024. View Scientific Paper →
Vitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization. Pharmaceutics. 2024;16(2):219. View Scientific Paper →